DGAP-Media: Proteo, Inc./ Proteo Biotech AG: Presentation of new preclinical data on Elafin at the ATS conference
(firmenpresse) - Proteo Biotech AG / Research/Technology
11.05.2010 12:22
Dissemination of a Media Release, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Irvine, CA - Kiel, May 11, 2010 - Proteo, Inc. (OTCBB: PTEO; Frankfurter
Freiverkehr: WKN: 925981) and its wholly-owned subsidiary Proteo Biotech AG
announced today that new preclinical data on Proteo's drug substance
Elafin will be presented on May 17 at the Annual International Conference
of the American Thoracic Society in New Orleans. This Conference is the
largest US meeting for healthcare professionals in pulmonary, critical
care, and sleep medicine.
Scientists from the Vera Moulton Wall Center for Pulmonary Vascular Disease
at the Stanford University School of Medicine studying this disease and its
treatments are communicating their latest results. They are presenting a
poster with the title»Adverse Pulmonary Effects of Mechanical Ventilation
in Newborn Mice Are Prevented or Attenuated by the Serine Elastase
Inhibitor Elafin«.
Preterm babies who require breathing support often develop chronic lung
disease which represents a considerable health risk with long term
consequences, notably increased susceptibility to recurrent childhood
respiratory ailments, and chronic lung disease in later life, such as
bronchial asthma and pulmonary emphysema. It is thought that
ventilation-induced inflammation in the lungs may be part of the cause.
The research was performed on a preclinical animal model for neonatal
chronic lung disease. The data show that in newborn mice mechanical
ventilation with oxygen-rich gas stimulates inflammation, causing
significant damage to the lungs such as elastic fiber degradation,
pulmonary cell death and activation of inflammatory mediators. The
resulting pulmonary injury also impairs lung growth. Treatment with Elafin
during mechanical ventilation largely prevented this inflammation.
The principal investigator at Stanford Dr. Richard Bland, specialist in
newborn medicine and neonatal lung disease: »The results raise hopes that
Elafin could be administered to infants to alleviate or prevent neonatal
chronic lung disease and its long-term consequences«.
Further information on the clinical development program for Elafin:
Proteo's drug substance Elafin is a natural human antagonist of elastase
and proteinase-3, two potent tissue destroyingenzymes, both of which
participate in the inflammatory mechanism of a variety of diseases.
Elafin's ability to block these inflammation promoting enzymes makes it a
promising drug candidate for the treatment of inflammatory lung diseases
and severe reperfusion injury. The excellent tolerability of intravenously
administered recombinant Elafin was demonstrated convincingly in a Phase I
clinical trial. The results of a Phase II clinical trial for the treatment
of postoperative inflammatory reactions of esophagus carcinoma are
currently being evaluated. Proteo's licensing and development partner,Minapharm Pharmaceuticals SAE, has initiated a further Phase II clinical
trial on the use of Elafin in kidney transplantation patients. This trial
is concerned with the prevention of acute organ rejection and chronic graft
injury (allograft nephropathy) and will be conducted at the University of
Cairo. As a further cooperation partner, the University of Edinburgh is
planning a clinical trial to test Elafin in the context of bypass surgery
after a heart attack.
Forward-Looking Statements:
Certain statements in this news release may contain forward-looking
information within the meaning of Rule 175 under the Securities Act of 1933
and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to
the safe harbor created by those rules. All statements, other than
statements of fact included in this release, including, without limitation,
statements regarding potential future plans and objectives of the company,
are forward-looking statements that involve risks and uncertainties. There
can be no assurance that such statements will prove to be accurate and
actual results and future events could differ materially from those
anticipated in such statements. Technical complications that may arise
could prevent the prompt implementation of any strategically significant
plan(s) outlined above. The company cautions that these forward looking
statements and risks and uncertainties involved are further qualified by
other factors including, but not limited to those set forth in the
company's Form 10-K filing and other filings with the United States
Securities and Exchange Commission. The company undertakes no obligation to
publicly update or revise any statements in this release, whether as a
result of new information, future events or otherwise.
Contact:
Barbara Kahlke, Ph.D.
Proteo Biotech AG
Am Kiel-Kanal 44
D-24106 Kiel
Email : info(at)proteo.de
Telephone: +49(0)431 8888462
Fax : +49(0)431 8888463
11.05.2010 12:22 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Bereitgestellt von Benutzer: EquityStory
" alt="Karim Akrawi Joins Simba Energy Board of DirectorsDatum: 11.05.2010 - 12:22 Uhr
Sprache: Deutsch
News-ID 20670
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 304 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-Media: Proteo, Inc./ Proteo Biotech AG: Presentation of new preclinical data on Elafin at the ATS conference"
steht unter der journalistisch-redaktionellen Verantwortung von
Proteo Biotech AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
